Chronic Kidney Disease

Apr 22, 2026

Cryoablation, the use of extreme cold to destroy abnormal tissue, has rapidly evolved from a niche surgical technique into one of the most versatile minimally invasive tools in modern medicine. By precisely delivering temperatures as low as –40°C to –170°C through specialized probes, cryoablation devices destroy ta...

Mar 25, 2026

Nephrotic syndrome is a complex renal disorder marked by excessive protein loss in the urine (greater than 40 mg/m²/hour), resulting in hypoalbuminemia (serum albumin below 30 g/L). This imbalance contributes to hyperlipidemia, edema, and a spectrum of systemic complications. The condition presents across age group...

Mar 17, 2026

Sana Biotechnology Reports Sustained Positive 14-Month Results from Type 1 Diabetes Islet Cell Transplant Study Without Immunosuppression Sana Biotechnology reported continued positive clinical results from its cell therapy programs, reinforcing its broader strategy of developing engineered cells as medicines. T...

Feb 11, 2026

Alport syndrome, an inherited disease, predominantly manifests in its X-linked form, constituting around 80% of cases. Without intervention, roughly 90% of affected males face kidney failure by age 40, whereas females typically experience a slower progression to this condition. Many Alport syndrome cases go unnotic...

Apr 21, 2025

The American College of Cardiology’s 74th Annual Scientific Session and Expo (ACC.25) convened from March 29 to March 31, 2025, in Chicago, Illinois, serving as a pivotal platform for the latest advancements in cardiovascular medicine. The conference attracted over 280 companies and organizations, showcasing innova...

Feb 03, 2025

The recent approval of OZEMPIC reinforces the growing trend of GLP-1 drugs being used for conditions beyond diabetes and weight loss. Novo Nordisk’s blockbuster GLP-1 medication, OZEMPIC, has secured another label expansion, as the FDA has now approved it for treating chronic kidney disease. The approval for chr...

Nov 12, 2024

FDA Approves Autolus's AUCATZYL for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia Autolus Therapeutics has achieved a significant milestone with FDA approval for AUCATZYL (obecabtagene autoleucel), a next-generation CAR T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic le...

Sep 27, 2024

On 11 September 2024, the latest results from the FLOW trial were presented at the European Association for the Study of Diabetes (EASD) conference in Madrid, Spain. The FLOW trial, initiated in 2019, was a global, multinational, randomized controlled trial conducted across 28 countries, 387 sites, and 3,533 partic...

Sep 27, 2024

Data from an integrated pooled analysis of finerenone across three Phase III trials involving heart failure, chronic kidney disease (CKD), and Type 2 diabetes (T2D) was presented at the 2024 European Association for the Study of Diabetes (EASD) Congress. This analysis was conducted with data from the FIDELIO-DKD2 a...

Apr 02, 2024

Voydeya Receives FDA Approval as Supplemental Treatment with Ravulizumab or Eculizumab for Managing Extravascular Hemolysis in Adult Patients with PNH Voydeya (danicopan) has received approval in the United States for use alongside ravulizumab or eculizumab in treating extravascular hemolysis (EVH) in adults dia...